Search

Your search keyword '"Marianna Aragri"' showing total 39 results
Start Over Author "Marianna Aragri" Language undetermined
39 results on '"Marianna Aragri"'

1. Establishment of a Seronegative Occult Infection With an Active Hepatitis B Virus Reservoir Enriched of Vaccine Escape Mutations in a Vaccinated Infant After Liver Transplantation

Author

Maria Concetta Bellocchi, Paola Francalanci, Rossana Scutari, L. Piermatteo, L. Carioti, Marco Ciotti, Romina Salpini, Maria Sole Basso, Mohammed Alkhatib, Marianna Aragri, Daniela Liccardo, Valentina Svicher, Manila Candusso, and Andrea Pietrobattista

Subjects
0301 basic medicine, Hepatitis B virus, medicine.medical_treatment, Liver transplantation, Virus Replication, medicine.disease_cause, Polymerase Chain Reaction, Virus, hepatitis B occult infection, Settore MED/07, law.invention, HBV reservoir, digital droplet PCR, liver transplantation, vaccine escape mutations, 03 medical and health sciences, 0302 clinical medicine, Antigen, law, medicine, Humans, Immunology and Allergy, Polymerase chain reaction, biology, Transmission (medicine), business.industry, Vaccination, Hepatitis B, Virology, 030104 developmental biology, Infectious Diseases, Liver, Child, Preschool, DNA, Viral, Mutation, biology.protein, Female, 030211 gastroenterology & hepatology, Antibody, business, Biomarkers
Abstract

We describe the establishment of a seronegative occult hepatitis B virus (HBV) infection (OBI) in a successfully vaccinated infant who underwent liver transplantation from an donor positive for antibody to hepatitis B core antigen (anti-HBc). The use of highly sensitive droplet digital polymerase chain reaction assays revealed a not negligible and transcriptionally active intrahepatic HBV reservoir (circular covalently closed DNA, relaxed circular DNA, and pregenomic RNA: 5.6, 2.4, and 1.1 copies/1000 cells, respectively), capable to sustain ongoing viral production and initial liver damage. Next-generation sequencing revealed a peculiar enrichment of hepatitis B surface antigen vaccine-escape mutations that could have played a crucial role in OBI transmission. This clinical case highlights the pathobiological complexity and the diagnostic challenges underlying OBI.

Published
2019
Full Text
View/download PDF

2. An Outbreak of Hepatitis C Virus Infection Among Transfused Thalassemia Patients: Root Cause Analysis, Phylogenetic Epidemiology and Antiviral Therapy

Author

Donatella Ferraro, Walter Mazzucco, Claudia Marotta, Francesco Di Raimondo, Marianna Aragri, Velia Chiara Di Maio, Stefania Grimaudo, Vito Di Marco, Maurizio Macaluso, Lavinia Fabeni, Rosaria Maria Pipitone, Fabrizio Bronte, and Francesca Ceccherini

Subjects
Ledipasvir, medicine.medical_specialty, Blood transfusion, Sofosbuvir, Transmission (medicine), business.industry, Hepatitis C virus, medicine.medical_treatment, medicine.disease_cause, Helsinki declaration, chemistry.chemical_compound, Chronic infection, chemistry, Internal medicine, Epidemiology, medicine, business, medicine.drug
Abstract

Background: Occurrence of HCV infection is reduced by effective risk management procedures, but patient-to-patient transmission continues to be reported in healthcare settings. We report an outbreak of 11 patients with HCV acute hepatitis (seven new infections and four re-infections) among 128 thalassemia patients followed at a Hospital in Sicily. Methods All patients with acute hepatitis and known chronic infection were tested for HCV-RNA, HCV genotyping, and NS3, NS5A and NS5B HCV-genomic regions sequencing. To identify transmission clusters we built phylogenetic trees for each gene employing Bayesian methods. Findings All patients with acute hepatitis were infected with HCV genotype 1b. Root-cause analysis, including a lookback procedure, led us to exclude blood donors as the source of HCV transmission. The phylogenetic analysis, conducted on seven patients with acute infection and eight patients with chronic infection, highlighted four transmission clusters including at least one patient with chronic and one patient with acute HCV infection. All patients in the same cluster received a blood transfusion at the Thalassemia Unit during the same day. Two patients with acute hepatitis spontaneously cleared HCV within four weeks and nine patients received ledipasvir plus sofosbuvir for six weeks, all achieving a sustained virological response. Interpretation Combined use of root cause analysis and molecular epidemiology was effective in ascertaining the origin of the HCV outbreak. Antiviral therapy avoided the chronic progression of the infection and further spread in care units and in the family environment. Funding Regional Health System of Sicily and by the Italian Ministry of Health (RF-2016-02362422). Declaration of Interest: V.D.M received speaking and/or consulting fees by Abbvie, Gilead, MSD, Intercept. F.C-S. received speaking and/or consulting fees by Abbvie, Gilead, Janssen, Merck/MSD, ViiV . All other authors have nothing to declare. Ethical Approval: This study was conducted in agreement with the Helsinki Declaration. Since the available DAAs were not licensed for acute hepatitis, the regional health authorities and local ethics committee authorized DAA therapy in patients with diagnosis of acute hepatitis

Published
2021
Full Text
View/download PDF

3. Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study

Author

Ada Bertoli, Valeria Cento, Luca Foroghi, Valeria Pace Palitti, Silvia Barbaliscia, Massimo Andreoni, Alessandro Pieri, Marianna Aragri, Carlo Federico Perno, Francesca Ceccherini-Silberstein, Giustino Parruti, Ennio Polilli, Velia Chiara Di Maio, Loredana Sarmati, and Elisabetta Teti

Subjects
0301 basic medicine, Microbiology (medical), medicine.medical_specialty, Cure rate, Settore MED/17 - Malattie Infettive, Genotype, Sustained Virologic Response, Personalized treatment, Administration, Oral, Context (language use), Hepacivirus, Microbial Sensitivity Tests, Antiviral Agents, Proof of Concept Study, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, medicine, Humans, In real life, Pharmacology (medical), Precision Medicine, Pharmacology, business.industry, Ribavirin, Sequence Analysis, DNA, Guideline, Hepatitis C, Chronic, Surgery, Discontinuation, Regimen, Treatment Outcome, 030104 developmental biology, Infectious Diseases, chemistry, RNA, Viral, 030211 gastroenterology & hepatology, business
Abstract

Background Pretreatment evaluation of HCV-infected patients is a complex interplay between multiple clinical and viral parameters, leading to a tailored approach that may bring real-life sustained virological response (SVR) rates close to 98%-99%. Objectives As proof-of-concept, we evaluated the efficacy of all-oral direct-acting antiviral (DAA) regimens in patients whose personalization included pre-therapy evaluation of natural resistance-associated substitutions (RASs), in addition to international guideline recommendations. Methods One hundred and thirty-one patients who started a first-line all-oral DAA regimen between April 2015 and December 2016 were tested for baseline NS3 and NS5A RASs by Sanger sequencing. SVR12 was defined as HCV-RNA undetectability 12 weeks after treatment discontinuation. Results Compatibly with a real-life context, 74.0% (97 of 131) of patients presented ≥2 pretreatment risk factors for failure to achieve SVR12 (infection by GT-1a/GT-3a; cirrhosis; previous treatment experience; HCV-RNA ≥800 000 IU/mL) and 33.6% had ≥3 risk factors. Natural RASs were frequently detected (32.1% prevalence), with substantial prevalence of NS5A RASs (15.3%), mostly represented by Y93H in GT-1b (3 of 36, 8.3%) and GT-3a (3 of 25, 12.0%) and F28C in GT-2c (2 of 11, 18.2%). Overall, personalized treatment led to 100% SVR12, even in those patients for whom treatment strategy was either strengthened (by ribavirin inclusion and/or duration increase) or simplified (by ribavirin exclusion and/or duration reduction), thanks to baseline RAS evaluation. Conclusions Even with newer DAA regimens, an integrated interpretation of clinical and virological pretreatment parameters, including natural RASs, may play a relevant role in bringing SVR rates close to the highest achievable. Treatment tailoring can be foreseen in 'hard-to-treat' patients, but also in 'easy' patients with favourable indicators, whereby a simplification/shortening of recommended regimens can be indicated.

Published
2017
Full Text
View/download PDF

4. Analysis of resistance and phylogenetic clusters in HCV-2c infected patients within the Italian network Vironet C

Author

Anna Claudia Pellicelli, Alessandro Pieri, Enzo Boeri, V. Pace Palitti, Roberto Gulminetti, V. Di Marco, Stefania Paolucci, Simona Landonio, F. Di Lorenzo, Laura Monno, L. Sarmati, Stefano Novati, Annapaola Callegaro, Simona Marenco, G. Raimondo, Lavinia Fabeni, Maurizio Zazzi, Silvia Barbaliscia, Nicola Coppola, P. Andreone, L. Carioti, Claudio Maria Mastroianni, Anna Licata, Fausto Baldanti, M. Andreoni, M. Quartini, M. Lichtner, Gloria Taliani, Laura Ambra Nicolini, Francesca Ceccherini-Silberstein, C.F. Perno, Luca Foroghi, Giustino Parruti, Bianca Bruzzone, Caterina Pasquazzi, C. Paternoster, Martina Milana, Sergio Babudieri, K. Yu La Rosa, M. Puoti, Hamid Hasson, Teresa Pollicino, N. Iapadre, C. Minichini, Raffaele Cozzolongo, Valeria Micheli, Barbara Rossetti, Aldo Bertoli, Elisabetta Teti, Marianna Aragri, Antonio Craxì, Filomena Morisco, V.C. Di Maio, Vincenzo Sangiovanni, Leonardo Baiocchi, and Mario Angelico

Subjects
Genetics, Hepatology, Resistance (ecology), Phylogenetic tree, business.industry, Gastroenterology, Medicine, business
Published
2020
Full Text
View/download PDF

5. VIRONET-C real life experience of resistance-guided retreatment in HCV infected patients who previously failed a NS5A inhibitor-containing regimen

Author

Mario Starace, Valerio Giannelli, Nunzia Cuomo, Vanni Borghi, Aldo Bertoli, Anna Licata, Anna Claudia Pellicelli, C. Minichini, M. Andreoni, M. Di Stefano, Giuseppe Cariti, Enzo Boeri, Raffaele Cozzolongo, Roberto Gulminetti, E. Milano, Valeria Cento, Elisabetta Degasperi, Laura Sighinolfi, A. Raddi, Ivana Maida, Barbara Rossetti, Teresa Santantonio, Valeria Micheli, C. Masetti, P. Andreone, Giustino Parruti, F. Di Lorenzo, Ilaria Lenci, Tiziano Allice, Annapaola Callegaro, Elisa Biliotti, M. Lichtner, Teresa Pollicino, Pietro Lampertico, Gloria Taliani, Caterina Pasquazzi, Piero Colombatto, Alessia Giorgini, G. Raimondo, Antonio Craxì, Francesca Ceccherini-Silberstein, Filomena Morisco, Valeria Ghisetti, V.C. Di Maio, Giuliano Rizzardini, Silvia Galli, Stefania Paolucci, A. De Santis, A. Lleo, Vincenzo Sangiovanni, A. Ciancio, Maurizio Zazzi, Elisabetta Teti, Simona Marenco, William Gennari, Stefano Novati, Giovanni Cenderello, Simona Landonio, Manuela Merli, A. Scuteri, Nicola Coppola, C.F. Perno, Giulia Morsica, I. Beretta, Claudio Maria Mastroianni, Simona Francioso, Mario Angelico, Laura Ambra Nicolini, Chiara Dentone, Silvia Barbaliscia, G.B. Gaeta, Marianna Aragri, Ennio Polilli, L. Donnarumma, Vincenza Calvaruso, Bianca Bruzzone, Fausto Baldanti, V. Pace Palitti, Roberto Ganga, Maurizia Rossana Brunetto, C. Paternoster, Sergio Babudieri, M. Puoti, Hamid Hasson, and M. Rendina

Subjects
medicine.medical_specialty, Regimen, Hepatology, business.industry, Internal medicine, Gastroenterology, medicine, business, NS5A
Published
2020
Full Text
View/download PDF

6. THU-133-Resistance-guided retreatment of HCV infected patients with a previous failure to an NS5A inhibitor-containing regimen: Italian real life experience

Author

Ada Bertoli, Gloria Taliani, Ilaria Lenci, Stefano Novati, Teresa Santantonio, Raffaele Cozzolongo, C. Masetti, Nunzia Cuomo, Laura Donnarumma, Giovanni Cenderrello, Silvia Barbaliscia, Adriano De Santis, Bianca Bruzzone, Giovanni Raimondo, Massimo Puoti, Carlo Federico Perno, Simona Landonio, Roberto Gulminetti, Elisabetta Degasperi, Giustino Parruti, Vincenza Calvaruso, Marianna Aragri, Teresa Pollicino, Pietro Lampertico, Laura Ambra Nicolini, Velia Chiara Di Maio, Valeria Ghisetti, Adriano M. Pellicelli, Ivana Maida, Caterina Pasquazzi, Valeria Cento, Roberto Ganga, Coppola Nicola, C. Paternoster, Maurizia Rossana Brunetto, Alessia Ciancio, Sergio Babudieri, Massimo Andreoni, Silberstein Francesca Ceccherini, Maurizio Zazzi, Maria Rendina, Miriam Lichtner, Angelico Mario, Ennio Polilli, Giuliano Rizzardini, Vanni Borghi, Maria Paola Callegaro, Valeria Pace Palitti, Stefania Paolucci, Carmine Minichini, Simona Marenco, Antonio Craxì, Filomena Morisco, Vincenzo Sangiovanni, Giulia Morsica, Valeria Micheli, Elisabetta Teti, and Pietro Andreone

Subjects
medicine.medical_specialty, Regimen, Hepatology, business.industry, Internal medicine, medicine, NS5A, business
Published
2019
Full Text
View/download PDF

7. SAT-190-Specific genetic elements in HBsAg C-terminus profoundly affect HBsAg levels in vivo, hamper HBsAg secretion in vitro and alter HBsAg structural stability in HBeAg-negative chronic HBV genotype D infection

Author

Patrick T F Kennedy, Ada Bertoli, Carlo Federico Perno, Massimo Marignani, Jens Verheyen, Paoloni Maurizio, L. Carioti, T. Mari, Vincenzo Malagnino, Carlotta Cerva, L. Colagrossi, Angelico Mario, Giustino Parruti, Jacopo Vecchiet, A. Battisti, Francesca Ceccherini Silberstein, A. Iuvara, Olympia E. Anastasiou, Upkar S. Gill, Claudio Maria Mastroianni, Miriam Lichtner, L. Piermatteo, Giuseppe Maria De Sanctis, Caterina Pasquazzi, Romina Salpini, Sandro Grelli, Massimo Andreoni, N. Iapadre, Loredana Sarmati, Marianna Aragri, and Valentina Svicher

Subjects
HBsAg, Hepatology, Hbeag negative, In vivo, C-terminus, Hbv genotype, Secretion, Biology, Affect (psychology), Virology, In vitro
Published
2019
Full Text
View/download PDF

8. SAT-159-Genetic determinants in critical domains of NS5A are associated with genotype 1b HCV-induced hepatocellular carcinoma

Author

Rossana Scutari, Valeria Cento, C. Masetti, Elisabetta Teti, Francesca Ceccherini Silberstein, Cristina Mussini, Massimo Andreoni, Ada Bertoli, Simona Francioso, Caterina Pasquazzi, Marianna Aragri, Silvia Barbaliscia, Carlo Federico Perno, Vincenza Calvaruso, Ivana Maida, Giustino Parruti, Valentina De Murtas, Angelica Sacco, Velia Chiara Di Maio, Mohammad Alkhatib, Ilaria Lenci, Federica Sozio, Angelico Mario, Alessandro Pieri, Maria Mercedes Santoro, Vanni Borghi, Antonio Craxì, Filomena Morisco, Valeria Pace Palitti, Romina Salpini, Valentina Svicher, Sergio Babudieri, Ennio Polilli, and P. Cacciatore

Subjects
Hepatology, Genotype 1b, Hepatocellular carcinoma, medicine, Cancer research, Biology, NS5A, medicine.disease
Published
2019
Full Text
View/download PDF

9. Characterization of baseline factors associated with treatment outcome in HCV-infected patients naive to direct acting antivirals: particular focus on natural resistance

Author

M. Siciliano, Giulia Morsica, Anna Claudia Pellicelli, Silvia Galli, F. Ceccherini-Silberstein, Fausto Baldanti, Bianca Bruzzone, R. Campoli, Giuliano Rizzardini, Vincenza Calvaruso, Gloria Taliani, V. Pace Palitti, C. Masetti, P Paba, Antonio Craxì, Filomena Morisco, Ennio Polilli, V.C. Di Maio, Martina Milana, William Gennari, C.F. Perno, Rossana Scutari, Aldo Bertoli, Valeria Cento, M. Andreoni, V. Boccaccio, Marianna Aragri, G.B. Gaeta, M. Lichtner, Caterina Pasquazzi, Vanni Borghi, Laura Ambra Nicolini, Renato Maserati, G. Fiorentino, Sergio Babudieri, Elisabetta Degasperi, Giustino Parruti, Mario Angelico, L. Foroghi, Valeria Ghisetti, Silvia Barbaliscia, Carlo Magni, Valeria Micheli, Elisabetta Teti, Nicola Coppola, Stefania Paolucci, L. Sarmati, R. D’Ambrosio, Pietro Lampertico, M. Puoti, N. Iapadre, Stefano Bonora, and V. Guarneri

Subjects
Natural resistance, Oncology, Focus (computing), medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Treatment outcome, Gastroenterology, medicine, Baseline (configuration management), DIRECT ACTING ANTIVIRALS, business
Published
2019
Full Text
View/download PDF

10. Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience

Author

Pietro Lampertico, Valeria Cento, Claudio Maria Mastroianni, M. Puoti, Giuliano Rizzardini, Maurizio Zazzi, M. Lichtner, Bianca Bruzzone, Ivana Maida, Elisabetta Degasperi, C.F. Perno, M. Rendina, Giustino Parruti, Vincenza Calvaruso, Gloria Taliani, F. Di Lorenzo, Ilaria Lenci, Anna Claudia Pellicelli, Caterina Pasquazzi, Stefania Paolucci, A. Raddi, Marianna Aragri, Ennio Polilli, Giulia Morsica, Mario Starace, M. Andreoni, M. Di Stefano, C. Minichini, L. Donnarumma, V. Guarneri, Simona Marenco, Simona Landonio, Raffaele Cozzolongo, V. Pace Palitti, N. Cuomo, P. Andreone, Nicola Coppola, Silvia Galli, Mario Angelico, C. Paternoster, Roberto Ganga, Vanni Borghi, Elisabetta Teti, Sergio Babudieri, Silvia Barbaliscia, Anna Licata, Giovanni Cenderello, Antonio Craxì, Filomena Morisco, Maurizia Rossana Brunetto, V.C. Di Maio, Vincenzo Sangiovanni, A. Ciancio, Piero Colombatto, Valeria Micheli, Teresa Pollicino, Laura Ambra Nicolini, Alessia Giorgini, Valeria Ghisetti, S. Novati, Annapaola Callegaro, Aldo Bertoli, E. Milano, Roberto Gulminetti, A. De Santis, F. Ceccherini-Silberstein, Teresa Santantonio, C. Masetti, G. Raimondo, Di Maio, V.C., Aragri, M., Masetti, C., Paolucci, S., Bruzzone, B., Degasperi, E., Barbaliscia, S., Pollicino, T., Minichini, C., Calvaruso, V., Rendina, M., Cento, V., Teti, E., Micheli, V., Ghisetti, V., Polilli, E., Palitti, V. Pace, Landonio, S., Lenci, I., Donnarumma, L., Nicolini, L.A., Bertoli, A., Starace, M., Pasquazzi, C., Callegaro, A.P., Morisco, F., Cenderello, G., Marenco, S., Gulminetti, R., Novati, S., Guarneri, V., Andreone, P., Galli, S., Ciancio, A., Sangiovanni, V., Cuomo, N., Raddi, A., Morsica, G., Borghi, V., Maida, I., Brunetto, M., Colombatto, P., Cozzolongo, R., De Santis, A., Lichtner, M., Babudieri, S., Taliani, G., Santantonio, T., Di Stefano, M., Paternoster, C., Ganga, R., Puoti, M., Rizzardini, G., Pellicelli, A., Milano, E., Mastroianni, C., Licata, A., Di Lorenzo, F., Giorgini, A., Lampertico, P., Parruti, G., Coppola, N., Zazzi, M., Raimondo, G., Andreoni, M., Craxì, A., Angelico, M., Perno, C.F., and Ceccherini-Silberstein, F.

Subjects
Resistance test, medicine.medical_specialty, Hepatology, business.industry, Gastroenterology, DAA failur, Vironet C, NS5A, Regimen, Internal medicine, medicine, retreatment, business
Abstract

Previous article in issueNext article in issue Introduction: There is a limited documentation about the retreatment of patients failing a recommended NS5A-containing regimen in Italy. Materials & methods: Within the VIRONET-C network, 386 NS5A-failing patients infected with different HCV-genotypes (GT) (GT1a/1b/2a-c/3a-b-g-h/4a-d-n-o-v=93/124/19/112/38) were analyzed. Retreatment of 105 failures was investigated. HCV-resistance-test was performed by Sanger-sequencing. Results: Failures following seven different NS5A-containing regimens were studied: 3D/2D (paritaprevir/ombitasvir ± dasabuvir) ± ribavirin (N = 72/4), daclatasvir/ledipasvir/velpatasvir + sofosbuvir ± ribavirin (N = 105/131/20), grazoprevir/elbasvir ± ribavirin (N = 34), glecaprevir/pibrentasvir (N = 20). Notably, 18.1% of NS5A-failing patients did not show any resistance-associated-substitutions (RAS), while 81.9% showed at least one NS5A-RAS, with multiclass-resistance in 35.5%. NS5A-RAS were observed more frequently in glecaprevir/pibrentasvir failures (GT1a 83.3%: Y93H + Q30H/D or +H58D; GT3a: 83.3% Y93H + A30K/G or +L31I) compared to sofosbuvir/velpatasvir (GT1a 16.6%: Y93H + Q30H, p = 0.08; GT3a 20.0%: Y93H/N + A30K/T, p = 0.03). To date, 105 failures have started a retreatment: sofosbuvir/velpatasvir ± ribavirin (N = 30), sofosbuvir/velpatasvir/voxilaprevir ± ribavirin (N = 67), glecaprevir/pibrentasvir (N = 4), grazoprevir/elbasvir ± sofosbuvir + ribavirin (N = 3), 3D + sofosbuvir + ribavirin (N = 1). The majority of patients were cirrhotic (51.9%) and relapsers (87.5%). The prevalence of NS5A-RASs before retreatment was 80.9%, with multiclass-resistance 29.5%. Among patients completing post-retreatment follow-up, a sustained-viral-response at week 12 (SVR12) was observed in 26/33 (78.8%). SVR4 was documented in 49/56 (87.5%). SVR12 was 76.0% with sofosbuvir/velpatasvir ± ribavirin (N = 25). Differently, SVR12 was 100% with glecaprevir/pibrentasvir for 8/12/16 weeks (N = 3), grazoprevir/elbasvir ± sofosbuvir + ribavirin for 12/24 weeks (N = 3) or 3D + sofosbuvir + ribavirin for 24 weeks (N = 1), despite the presence of NS5A-RASs. Until now, 67 patients started sofosbuvir/velpatasvir/voxilaprevir ± ribavirin recommended-retreatment for 12 weeks. 54/67 (80.6%) showed at least one baseline NS5A-RAS, 23/67 (34.3%) multiple-NS5A-RASs, and 22/67 (32.8%) multiclass-resistance. Of 25 patients with available outcome, 96.0% had SVR4. Only 1 GT1b infected patient was non-responder, without RASs before retreatment. Conclusions: In this real-life setting, NS5A-RASs were frequently detected at failure, and multiclass-resistance was around 30%. Overall, SVR after resistance-test-guided retreatment was >95%, with the exception of the sofosbuvir/velpatasvir retreatment. Our results show how HCV resistance-test at failure may be useful to optimize retreatment strategies.

Published
2019
Full Text
View/download PDF

11. Comparison of resistance profiles among DAA-naive and DAA-experienced patients infected with HCV non-1 genotype in Italy

Author

Simona Francioso, A. Ciaccio, Teresa Pollicino, Bianca Bruzzone, G. Fiorentino, V. Boccaccio, Coppola Nicola, M. Puoti, Ivana Maida, Valeria Cento, Lucio Boglione, Francesca Ceccherini Silberstein, Valeria Micheli, Silvia Barbaliscia, Sergio Babudieri, Guido Gubertini, Giustino Parruti, Antonio Craxì, Vincenzo Vullo, Ennio Polilli, M. Andreoni, Filomena Morisco, Vincenzo Sangiovanni, Vincenza Calvaruso, Renato Maserati, Velia Chiara Di Maio, Maurizio Zazzi, Marianna Aragri, A. Ciancio, Barbara Rossetti, Anna Claudia Pellicelli, Elisabetta Teti, C.F. Perno, Caterina Pasquazzi, L. Sarmati, R. D’Ambrosio, Mario Angelico, Fosca Niero, Stefano Bonora, M. Rendina, Gloria Taliani, Luca Foroghi, Laura Ambra Nicolini, Aldo Bertoli, A. Lleo, G. Raimondo, T. Ruggiero, Simona Marenco, Valeria Pace Palitti, G.B. Gaeta, Stefania Paolucci, and Ilaria Lenci

Subjects
Hepatology, Resistance (ecology), business.industry, Genotype, Medicine, business, Virology
Published
2018
Full Text
View/download PDF

12. On treatment HCV-RNA evaluation in real-life: Still a role in the era of direct acting antiviral agents?

Author

Angelico Mario, Ilaria Lenci, Valeria Micheli, L. Sarmati, Giuliano Rizzardini, C.F. Perno, M. Andreoni, Guido Gubertini, Elisabetta Teti, Simona Francioso, Francesca Ceccherini Silberstein, Valeria Cento, Monica Schiavini, Marco Ciotti, C. Masetti, Simone Passerini, Carlo Magni, Marianna Aragri, V.C. Di Maio, Aldo Bertoli, and Martina Milana

Subjects
Hepatology, business.industry, In real life, Medicine, business, Virology, Direct acting
Published
2018
Full Text
View/download PDF

13. National quality control and validation of hepatitis C NS3, NS5A and NS5B genotypic resistance testing

Author

M.P. Callegaro, A. Lai, Enzo Boeri, G. Raimondo, E. Galmozzi, Francesca Ceccherini Silberstein, N. Cuomo, M.A.D. Stefano, Valeria Micheli, Antonio Craxì, C.F. Perno, M. Arosio, Fausto Baldanti, C. Minosse, Stefania Paolucci, Maurizio Zazzi, Maria Rosaria Capobianchi, Rosaria Santangelo, Coppola Nicola, M. L. Vatteroni, Maurizio Sanguinetti, Marianna Aragri, Valeria Cento, Giuseppina Raffa, Teresa Pollicino, Maurizia Rossana Brunetto, C. Caudai, S. Soldini, Silvia Galli, Stefano Menzo, T. Ruggiero, Valeria Ghisetti, William Gennari, D. Cavallone, Anna Rosa Garbuglia, Bianca Bruzzone, T. Santantonio, A. Raddi, Mario Starace, and Laura Monno

Subjects
NS3, Hepatology, business.industry, media_common.quotation_subject, Hepatitis C, Biology, medicine.disease, Biotechnology, chemistry.chemical_compound, chemistry, medicine, Genotypic resistance, Quality (business), business, NS5A, NS5B, media_common
Published
2018
Full Text
View/download PDF

14. Key mutational patterns in HBsAg C-terminus profoundly affect HBsAg levels in HBeAg-negative chronic HBV genotype D infection

Author

A. Battisti, Olympia E. Anastasiou, Giuseppe Maria De Sanctis, Lavinia Fabeni, Caterina Pasquazzi, L. Carioti, Patrick T F Kennedy, Domenico Di Carlo, T. Mari, Jens Verheyen, Sandro Grelli, V. Svicher, Mario Angelico, J. Vecchiet, R. Salpini, M. Andreoni, L. Sarmati, Luna Colagrossi, A. Iuvara, Marianna Aragri, M. Lichtner, Giustino Parruti, Massimo Marignani, Aldo Bertoli, L. Piermatteo, V. Fini, Carlotta Cerva, U.S. Gill, Claudio Maria Mastroianni, Francesca Ceccherini Silberstein, P. Maurizio, C.F. Perno, Vincenzo Malagnino, and N. Iapadre

Subjects
HBsAg, Hepatology, Hbeag negative, C-terminus, Medizin, Hbv genotype, Biology, Affect (psychology), Virology
Published
2018
Full Text
View/download PDF

15. Characterization of resistance profiles in HCV 2-3-4 DAA-naïve and DAA-experienced infected patients in Italy

Author

V. Boccaccio, Irene Maida, Ennio Polilli, Alessandro Ciaccio, Ilaria Lenci, Anna Claudia Pellicelli, Marilena Rendina, Fabio Niero, Guido Gubertini, Mario Angelico, T. Ruggiero, Stefano Bonora, Barbara Rossetti, Caterina Pasquazzi, Niccolò Gabriele Coppola, Simona Francioso, Silvia Barbaliscia, M. Puoti, M. Andreoni, L. Foroghi, L. Sarmati, Silvia Paolucci, Giuliana Fiorentino, Teresa Pollicino, G.B. Gaeta, C.F. Perno, Giustino Parruti, Valeria Cento, Laura Ambra Nicolini, Gloria Taliani, Elisabetta Teti, Lucio Boglione, Asia Bertoli, Sergio Babudieri, Valeria Micheli, Renato Maserati, Marianna Aragri, F. Ceccherini-Silberstein, Vincenzo Vullo, A. R. D’Ambrosio, Simona Marenco, A. Lleo, Antonio Craxì, Filomena Morisco, V.C. Di Maio, Vincenzo Sangiovanni, Maurizio Zazzi, Vincenza Calvaruso, Alessia Ciancio, V. Pace Palitti, Bianca Bruzzone, and Giacomo Raimondo

Subjects
Hepatology, business.industry, Gastroenterology, Medicine, business, Virology
Published
2018
Full Text
View/download PDF

16. National quality control and validation of hepatitis C NS3, NS5A and NS5B genotypic resistance testing

Author

Valeria Cento, Maurizio Zazzi, Teresa Pollicino, Anna Rosa Garbuglia, S. Soldini, M. Arosio, Silvia Galli, A. Raddi, Annapaola Callegaro, Enzo Boeri, Marianna Aragri, Valeria Ghisetti, C. Minosse, N. Cuomo, Rosaria Santangelo, Daniela Cavallone, M. L. Vatteroni, Maurizia Rossana Brunetto, Nicola Coppola, Giuseppina Raffa, T. Santantonio, A. Lai, G. Raimondo, M. Di Stefano, C.F. Perno, Stefania Paolucci, Antonio Craxì, Valeria Micheli, William Gennari, T. Ruggiero, F. Ceccherini-Silberstein, E. Galmozzi, Mario Starace, Michela Sampaolo, Bianca Bruzzone, Laura Monno, Maria Rosaria Capobianchi, Maurizio Sanguinetti, C. Caudai, Stefano Menzo, and Fausto Baldanti

Subjects
0301 basic medicine, NS3, Hepatology, business.industry, media_common.quotation_subject, Gastroenterology, Hepatitis C, medicine.disease, Biotechnology, 03 medical and health sciences, chemistry.chemical_compound, 030104 developmental biology, chemistry, medicine, Genotypic resistance, Quality (business), business, NS5A, NS5B, media_common
Published
2018
Full Text
View/download PDF

17. NS5A gene analysis by next generation sequencing in HCV nosocomial transmission clusters of HCV genotype 1b infected patients

Author

Stefania Grimaudo, Lavinia Fabeni, Giuseppina Brancaccio, Carlo Federico Perno, Marco Cantone, L. Carioti, Antonio Pinto, M.C. Sorbo, Giovanni Battista Gaeta, Maria Concetta Bellocchi, Francesca Ceccherini-Silberstein, Velia Chiara Di Maio, Antonio Craxì, Vito Di Marco, Marianna Aragri, Ferdinando Frigeri, Fabrizio Bronte, Silvia Barbaliscia, Walter Mazzucco, Rosaria Maria Pipitone, Bellocchi, Maria Concetta, Aragri, Marianna, Carioti, Luca, Fabeni, Lavinia, Pipitone, Rosaria Maria, Brancaccio, Giuseppina, Sorbo, Maria Chiara, Barbaliscia, Silvia, Di Maio, Velia Chiara, Bronte, Fabrizio, Grimaudo, Stefania, Mazzucco, Walter, Frigeri, Ferdinando, Cantone, Marco, Pinto, Antonio, Perno, Carlo Federico, Craxì, Antonio, Gaeta, Giovanni Battista, Di Marco, Vito, and Ceccherini-Silberstein, Francesca

Subjects
Male, 0301 basic medicine, viruses, Drug Resistance, Hepacivirus, Viral Nonstructural Proteins, medicine.disease_cause, Settore MED/42 - Igiene Generale E Applicata, Gastroenterology, Settore MED/07, chemistry.chemical_compound, 0302 clinical medicine, Genotype 1b, Medicine, Viral, lcsh:QH301-705.5, Phylogeny, Cross Infection, nosocomial transmission, High-Throughput Nucleotide Sequencing, virus diseases, HCV, NGS, acute infection, chronic infection, sequencing, Acute Disease, Adult, Amino Acid Substitution, Antiviral Agents, Blood Transfusion, Chronic Disease, Drug Resistance, Viral, Female, Genotype, Hepatitis C, Host-Pathogen Interactions, Humans, Interferons, Middle Aged, Polymorphism, Single Nucleotide, beta-Thalassemia, Single Nucleotide, General Medicine, 030211 gastroenterology & hepatology, medicine.medical_specialty, Hepatitis C virus, Viral quasispecies, Article, DNA sequencing, 03 medical and health sciences, Internal medicine, Polymorphism, NS5A, NS5B, Gene, Hepatology, business.industry, Nosocomial transmission, biochemical phenomena, metabolism, and nutrition, Virology, digestive system diseases, Chronic infection, 030104 developmental biology, chemistry, lcsh:Biology (General), business
Abstract

Background: The aim of the study was to investigate the intra-host variability through next-generation-sequencing (NGS) of the NS5A-gene in nosocomial transmission-clusters observed in two Italian hospitals among hepatitis C virus (HCV)-genotype-1b infected patients. Methods: HCV-sequencing was performed by Sanger-sequencing (NS3 + NS5A + NS5B) and by NGS (NS5A, MiSeq-Illumina) in 15 HCV-1b infected patients [five acute with onco-hematologic-disease and 10 (4/6 acute/chronic) with &beta, thalassemia]. Resistance-associated-substitutions (RAS) were analysed by Geno2pheno-algorithm. Nucleotide-sequence-variability (NSV, at 1%, 2%, 5%, 10% and 15% NGS-cutoffs) and Shannon entropy were estimated. Phylogenetic analysis was performed by Mega6-software and Bayesian-analysis. Results: Phylogenetic analysis showed five transmission-clusters: one involving four HCV-acute onco-hematologic-patients, one involving three HCV-chronic &beta, thalassemia-patients and three involving both HCV-acute and chronic &beta, thalassemia-patients. The NS5A-RAS Y93H was found in seven patients, distributed differently among chronic/acute patients involved in the same transmission-clusters, independently from the host-genetic IL-28-polymorphism. The intra-host NSV was higher in chronic-patients versus acute-patients, at all cutoffs analyzed (p &lt, 0.05). Even though Shannon-entropy was higher in chronic-patients, significantly higher values were observed only in chronic &beta, thalassemia-patients versus acute &beta, thalassemia-patients (p = 0.01). Conclusions: In nosocomial HCV transmission-clusters, the intra-host HCV quasispecies divergence in patients with acute-infection was very low in comparison to that in chronic-infection. The NS5A-RAS Y93H was often transmitted and distributed differently within the same transmission-clusters, independently from the IL-28-polymorphism.

Published
2019
Full Text
View/download PDF

18. Multiclass HCV resistance to interferon-free direct acting antivirals regimens in real life failures advocates for tailored second-line therapies

Author

Ilaria Lenci, A. Di Biagio, Giuliano Rizzardini, L. Marinaro, C. D'Ambrosio, Fausto Baldanti, Ivana Maida, G.B. Gaeta, M. Puoti, T. Ruggiero, Mario Angelico, Vincenza Calvaruso, Laura Sticchi, Mario Starace, Giustino Parruti, P. Cacciatore, Nicola Caporaso, Caterina Pasquazzi, Stefania Paolucci, Anna Claudia Pellicelli, M. Andreoni, C. Masetti, Sergio Babudieri, Gabriella d'Ettorre, Francesco Santopaolo, Raffaele Cozzolongo, P. Andreone, Carlo Magni, Valeria Cento, Guido Gubertini, J. Vecchiet, Stefano Novati, Nicola Coppola, C.F. Perno, Bianca Bruzzone, F. De Leonardis, V. Pace Palitti, Marianna Aragri, A. Grieco, Pierluigi Tarquini, G. De Stefano, G. Raimondo, Teresa Pollicino, Alessia Giorgini, Giorgio Barbarini, Valeria Ghisetti, G. Verucchi, M.C. Sorbo, Savino Bruno, M. Paoloni, F. Ceccherini-Silberstein, Roberto Gulminetti, Antonio Craxì, Filomena Morisco, Manuela Merli, V.C. Di Maio, Vincenzo Sangiovanni, A. Ciancio, Simona Francioso, Simona Landonio, Aldo Bertoli, A. Mancon, Valeria Micheli, Antonio Picciotto, V. Boccaccio, M. Melis, Ennio Polilli, F.P. Antonucci, Dante Romagnoli, and Silvia Barbaliscia

Subjects
Oncology, medicine.medical_specialty, Hepatology, business.industry, Interferon free, Gastroenterology, DIRECT ACTING ANTIVIRALS, 03 medical and health sciences, 0302 clinical medicine, Second line, 030220 oncology & carcinogenesis, Internal medicine, Medicine, In real life, 030211 gastroenterology & hepatology, business
Published
2017
Full Text
View/download PDF

19. The challenge of HCV-retreatment after DAA-failure: real-life experience advocates for caution

Author

Vincenza Calvaruso, C. Masetti, Silvia Barbaliscia, Bianca Bruzzone, Giustino Parruti, Sergio Babudieri, Marco Biolato, Marianna Aragri, C.F. Perno, Vincenzo Messina, Valeria Cento, Simona Landonio, M. Melis, Carmine Minichini, Valeria Micheli, F. Ceccherini-Silberstein, Lucio Boglione, Giorgio Barbarini, Mario Angelico, Aldo Bertoli, Monica Schiavini, Laura Ambra Nicolini, Ennio Polilli, Raffaele Cozzolongo, Carlo Magni, Chiara Baiguera, C. Dentone, Giuliano Rizzardini, Anna Claudia Pellicelli, M. Siciliano, Y. Troshina, Antonio Craxì, Filomena Morisco, M. Puoti, V.C. Di Maio, A. Ciancio, Ilaria Lenci, Laura Sticchi, Stefania Paolucci, T. Ruggiero, Simona Marenco, and Nicola Coppola

Subjects
0301 basic medicine, 03 medical and health sciences, medicine.medical_specialty, 030104 developmental biology, 0302 clinical medicine, Hepatology, business.industry, Immunology, medicine, 030211 gastroenterology & hepatology, Intensive care medicine, business
Published
2017
Full Text
View/download PDF

20. Multiclass hepatitis C virus resistance to direct acting antivirals in real life interferon-free regimens failures advocates for tailored second-line therapies

Author

A. Grieco, Valeria Cento, Savino Bruno, M. Paoloni, Anna Claudia Pellicelli, Gabriella d'Ettorre, Raffaele Cozzolongo, G.D. Stefano, Carlo Magni, V. Boccaccio, M. Andreoni, Fausto Baldanti, Silvia Barbaliscia, J. Vecchiet, Valeria Micheli, Antonio Picciotto, Giustino Parruti, Guido Gubertini, M. Melis, Pierluigi Tarquini, Francesca Ceccherini-Silberstein, Bianca Bruzzone, Sergio Babudieri, Antonio Di Biagio, M. Puoti, Manuela Merli, L. Marinaro, Mario Starace, Caterina Pasquazzi, Marianna Aragri, Antonio Craxì, Teresa Pollicino, Filomena Morisco, V.C. Di Maio, Alessia Giorgini, Vincenzo Sangiovanni, Giorgio Barbarini, Valeria Ghisetti, G. Verucchi, T. Ruggiero, Ivana Maida, P. Andreone, Vincenza Calvaruso, Giovanni Raimondo, C. D'Ambrosio, Simona Francioso, F.P. Antonucci, Dante Romagnoli, C.F. Perno, Mario Angelico, Ilaria Lenci, Alessia Ciancio, Roberto Gulminetti, G.B. Gaeta, Simona Landonio, Nicola Caporaso, Francesco Santopaolo, Nicola Coppola, Laura Sticchi, Valeria Pace Palitti, Stefania Paolucci, Aldo Bertoli, and A. Mancon

Subjects
0301 basic medicine, Hepatology, business.industry, Hepatitis C virus, Interferon free, medicine.disease_cause, DIRECT ACTING ANTIVIRALS, Virology, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Second line, medicine, In real life, 030211 gastroenterology & hepatology, business
Published
2017
Full Text
View/download PDF

21. Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression

Author

Matteo Surdo, L. Carioti, Maria Concetta Bellocchi, Valentina Svicher, Claudio Maria Mastroianni, M. Paoloni, Claudia Alteri, L. Colagrossi, Yoram Louzoun, Romina Salpini, Mariarosaria Esposito, Michela Pollicita, Carlo Federico Perno, Loredana Sarmati, Massimo Andreoni, Mario Angelico, Massimo Marignani, Cesare Sarrecchia, Chiara D'Amore, Marianna Aragri, Christina Becker, Fabiola Di Santo, Aldo Marrone, Miriam Lichtner, A. Ricciardi, Daniele Armenia, Jens Verheyen, Salpini, R, Colagrossi, L, Bellocchi, Mc, Surdo, M, Becker, C, Alteri, C, Aragri, M, Ricciardi, A, Armenia, D, Pollicita, M, Di Santo, F, Carioti, L, Louzoun, Y, Mastroianni, Cm, Lichtner, M, Paoloni, M, Esposito, M, D'Amore, C, Marrone, A, Marignani, M, Sarrecchia, C, Sarmati, L, Andreoni, M, Angelico, M, Verheyen, J, Perno, Cf, Svicher, V, Marrone, Aldo, Verhejen, J, and Svicher, V.

Subjects
Male, HBsAg, Glycosylation, medicine.medical_treatment, Medizin, medicine.disease_cause, genetic variability, HBV, education.field_of_study, immunosuppression, biology, virus diseases, Immunosuppression, surface antigen, Hepatitis B, Middle Aged, Settore MED/07 - Microbiologia e Microbiologia Clinica, Rituximab, Female, Antibody, medicine.drug, Adult, medicine.medical_specialty, Hepatitis B virus, Settore MED/17 - Malattie Infettive, Population, Hepatitis B, Chronic, Internal medicine, Drug Resistance, Viral, medicine, Humans, Hepatitis B Antibodies, education, Aged, Immune Evasion, Immunosuppression Therapy, Hepatitis B Surface Antigens, Hepatology, business.industry, medicine.disease, Virology, digestive system diseases, Immunology, Mutation, biology.protein, Virus Activation, business
Abstract

Hepatitis B virus (HBV) reactivation during immunosuppression can lead to severe acute hepatitis, fulminant liver failure, and death. Here, we investigated hepatitis B surface antigen (HBsAg) genetic features underlying this phenomenon by analyzing 93 patients: 29 developing HBV reactivation and 64 consecutive patients with chronic HBV infection (as control). HBsAg genetic diversity was analyzed by population-based and ultradeep sequencing (UDS). Before HBV reactivation, 51.7% of patients were isolated hepatitis B core antibody (anti-HBc) positive, 31.0% inactive carriers, 6.9% anti-HBc/anti-HBs (hepatitis B surface antibody) positive, 6.9% isolated anti-HBs positive, and 3.4% had an overt HBV infection. Of HBV-reactivated patients, 51.7% were treated with rituximab, 34.5% with different chemotherapeutics, and 13.8% with corticosteroids only for inflammatory diseases. In total, 75.9% of HBV-reactivated patients (vs. 3.1% of control patients; P

Published
2015

22. Clinical relevance of accurate HCV genotype and subtype assignment by NS3/NS5A/NS5B direct sequencing in the era of new direct acting antiviral agents

Author

Carlo Magni, Francesca Ceccherini-Silberstein, M. Puoti, Claudio Maria Mastroianni, A. Di Biagio, Marco Romano, Filomena Morisco, Giustino Parruti, Antonio Gasbarrini, Gloria Taliani, M. Siciliano, Simona Landonio, V.C. Di Maio, Martina Milana, Laura Gianserra, F. Deodati, Caterina Pasquazzi, M. Andreoni, J. Vecchiet, Valeria Cento, L. Lambiase, Marianna Aragri, Simona Francioso, E. D’Amico, Gabriella d'Ettorre, Giuliano Rizzardini, D. Di Paolo, Antonio Grieco, F. De Leonardis, A. Manunta, Ivana Maida, Anna Claudia Pellicelli, Mario Angelico, K. Yu La Rosa, Miriam Lichtner, P. Cacciatore, Cesare Sarrecchia, F.P. Antonucci, Aldo Bertoli, Valeria Micheli, Antonio Picciotto, Dante Romagnoli, Savino Bruno, Laura Ambra Nicolini, Ilaria Lenci, C.F. Perno, Marco Ciotti, Lorenzo Nosotti, Simona Marenco, Elisabetta Teti, M. Tontodonati, Maria Stella Mura, R. Campoli, Nicola Caporaso, S. Grieco, Sergio Babudieri, and Umberto Vespasiani-Gentilucci

Subjects
Genetics, chemistry.chemical_compound, NS3, Hepatology, chemistry, Direct sequencing, Genotype, Gastroenterology, Clinical significance, Biology, NS5A, NS5B, Direct acting
Published
2016
Full Text
View/download PDF

23. Presence of resistance associated variants in patients with virological failure to new direct acting antivirals and requirement of unconventional regimens for re-treatment

Author

Antonio Craxì, Filomena Morisco, M. Puoti, V.C. Di Maio, Nicola Caporaso, Anna Claudia Pellicelli, Francesca Ceccherini-Silberstein, M. Paoloni, Maria Stella Mura, G.B. Gaeta, F.P. Antonucci, Vincenza Calvaruso, R. Campoli, Gianluca Brancaccio, D. Di Paolo, Dante Romagnoli, Antonio Grieco, K. Yu La Rosa, Stefano Brillanti, Valeria Cento, Caterina Pasquazzi, Ilaria Lenci, Manuela Merli, Simona Francioso, M.C. Sorbo, M. Melis, Marco Biolato, C.F. Perno, Marianna Aragri, Aldo Bertoli, Gabriella Verucchi, Sergio Babudieri, V. Pisani, Mario Angelico, Francesca Donato, and J. Vecchiet

Subjects
Oncology, medicine.medical_specialty, Hepatology, business.industry, Gastroenterology, DIRECT ACTING ANTIVIRALS, Virological failure, Surgery, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Medicine, 030211 gastroenterology & hepatology, In patient, business
Published
2016
Full Text
View/download PDF

24. P0912 : Early-phase HCV kinetics and role of pre-existing resistance in cirrhotic or interferon-insensitive patients on daclatasvir plus asunaprevir

Author

Francesca Ceccherini-Silberstein, Valeria Cento, Roberta Alfieri, F.P. Antonucci, Antonio Picciotto, Vincenza Calvaruso, S. Petta, Marianna Aragri, Antonio Craxì, Simona Marenco, C.F. Perno, Luciano Milanesi, V.C. Di Maio, and A. Mazzola

Subjects
chemistry.chemical_compound, Daclatasvir, Hepatology, chemistry, business.industry, Interferon, Kinetics, Asunaprevir, Medicine, Pharmacology, business, Early phase, medicine.drug
Published
2015
Full Text
View/download PDF

25. Natural HCV resistance is common in Italy and differently associated to genotypes

Author

Simona Landonio, Barbara Menzaghi, Giustino Parruti, T. Ruggiero, Valeria Cento, Francesca Ceccherini-Silberstein, Ilaria Lenci, M. Melis, Giuliano Rizzardini, Antonio Gasbarrini, P. Cacciatore, V. Pace Palitti, M.C. Sorbo, Ennio Polilli, Martina Milana, Alessandro Pieri, Laura Gianserra, Anna Claudia Pellicelli, P. Andreone, C. Masetti, Bianca Bruzzone, Simona Marenco, Elisabetta Teti, M. Andreoni, Gloria Taliani, Aldo Bertoli, Elisa Biliotti, Miriam Lichtner, Nicola Coppola, Vincenza Calvaruso, Fausto Baldanti, Stefania Paolucci, C.F. Perno, Carlo Magni, Sergio Babudieri, Valeria Micheli, Antonio Craxì, Filomena Morisco, V.C. Di Maio, Dante Romagnoli, Laura Ambra Nicolini, Mario Angelico, Loredana Sarmati, M. Siciliano, M. Puoti, N. Iapadre, Marianna Aragri, Vincenzo Vullo, Caterina Pasquazzi, and F. De Leonardis

Subjects
0301 basic medicine, Genetics, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Hepatology, Resistance (ecology), business.industry, Genotype, Gastroenterology, Medicine, 030211 gastroenterology & hepatology, business
Published
2017
Full Text
View/download PDF

26. Gain of positively charged amino acids at specific positions of HBsAg C-terminus tightly correlates with HBV-induced hepatocellular carcinoma by altering the structural folding of this domain

Author

Luna Colagrossi, Giuseppina Cappiello, Hervé Fleury, N. Iapadre, Alberto Spanò, Aldo Bertoli, A. Ricciardi, Simona Francioso, C.F. Perno, Marianna Aragri, F. Ceccherini-Silberstein, V. Svicher, J. Vecchiet, R. Salpini, R. Longo, Giustino Parruti, Caterina Pasquazzi, Mario Angelico, L. Piermatteo, Lavinia Fabeni, A. Battisti, Pascale Trimoulet, Ilaria Lenci, T. Mari, A. Barlattani, L. Carioti, Domenico Di Carlo, S. Romano, L. Sarmati, and M. Andreoni

Subjects
chemistry.chemical_classification, Folding (chemistry), HBsAg, Hepatology, chemistry, Biochemistry, Hepatocellular carcinoma, C-terminus, Domain (ring theory), medicine, medicine.disease, Amino acid
Published
2017
Full Text
View/download PDF

27. P1235 BASELINE/EARLY PRESENCE OF KNOWN AND NOVEL RESISTANCE MUTATIONS IS ASSOCIATED WITH VIRAL FAILURE IN DIFFICULT-TO-TREAT PATIENTS TREATED WITH FIRST GENERATION PROTEASE INHIBITORS

Author

C.F. Perno, Alessandro Gasbarrini, Marianna Aragri, J. Vecchiet, M. Andreoni, Carlo Magni, Ilaria Lenci, Valeria Cento, F.P. Antonucci, Daniele Armenia, Simona Landonio, Laura Ambra Nicolini, D. Di Paolo, M. Siciliano, M. Tontodonati, Giustino Parruti, Maria Concetta Bellocchi, Sergio Babudieri, Anna Claudia Pellicelli, Mario Angelico, Maria Stella Mura, Giuliano Rizzardini, Cesare Sarrecchia, F. De Leonardis, Gloria Taliani, F. Ceccherini-Silberstein, V.C. Di Maio, Alessandro Mancon, A. Di Biagio, Lorenzo Nosotti, Valeria Micheli, and A. Manunta

Subjects
Protease, Hepatology, business.industry, medicine.medical_treatment, medicine, Baseline (configuration management), business, Virology, First generation
Published
2014
Full Text
View/download PDF

28. A recent epidemiological cluster of acute hepatitis B genotype F1b infection in a restricted geographical area of Italy

Author

A. Ranelli, Giustino Parruti, Carlo Federico Perno, M. Dalessandro, Claudia Alteri, A. Battisti, Maria Concetta Bellocchi, M. Paoloni, Daniele Armenia, Valentina Svicher, Romina Salpini, L. Colagrossi, Marianna Aragri, R. Mariani, L. Carioti, Michela Pollicita, and Lavinia Fabeni

Subjects
Adult, Male, Microbiology (medical), Hepatitis B virus, medicine.medical_specialty, Unprotected Sexual Intercourse, Sexual transmission, genotype, medicine.disease_cause, Disease cluster, vaccine, Genotype, Epidemiology, HBV, Humans, Medicine, Phylogeny, epidemiological cluster, business.industry, High-Throughput Nucleotide Sequencing, Acute infection, Sequence Analysis, DNA, Sexually Transmitted Diseases, Viral, General Medicine, Middle Aged, Hepatitis B, Settore MED/07 - Microbiologia e Microbiologia Clinica, medicine.disease, Virology, Vaccination, Phylogeography, Infectious Diseases, Italy, DNA, Viral, Immunology, Female, business
Abstract

In this study, by phylogenetic analysis, we identified an epidemiological cluster involving eight individuals diagnosed with acute hepatitis B virus (HBV) infection related to unprotected sexual intercourse in a restricted area of central Italy (time period: 2011–2014). Notably, these patients (six of eight Italians) were infected by subgenotype F1b, which is not commonly found in western countries. Ultra-deep pyrosequencing confirmed a superimposable composition of HBV quasi-species in these patients. Despite the availability of effective vaccination, this study highlights the importance of not underestimating the risk of HBV infection, of continuing to set up surveillance programmes for HBV infection, and of investigating the pathogenetic potential of these atypical genotypes.

Published
2015
Full Text
View/download PDF

29. P0915 : Clinical relevance of baseline/early detection and persistence of resistant associated variants in HCV-1 patients treated with protease-inhibitors assessed by ultra-deep sequencing

Author

Francesca Ceccherini-Silberstein, Valeria Cento, Valeria Micheli, Antonio Picciotto, M. Santoro, Marianna Aragri, M. Andreoni, Ilaria Lenci, D. Di Paolo, Aldo Bertoli, Carlo Magni, Mario Angelico, M. Tontodonati, S. Bruno, Maria Concetta Bellocchi, Daniele Armenia, Cesare Sarrecchia, Maria Stella Mura, Gloria Taliani, Giuliano Rizzardini, F.P. Antonucci, Sergio Babudieri, F. De Leonardis, C.F. Perno, A. De Maria, A. Manunta, Giustino Parruti, Filomena Morisco, M. Puoti, V.C. Di Maio, J. Vecchiet, F. De Luca, Lorenzo Nosotti, Simona Francioso, Ennio Polilli, and L. Carioti

Subjects
Oncology, medicine.medical_specialty, Protease, Hepatology, business.industry, medicine.medical_treatment, Early detection, Ultra deep sequencing, Bioinformatics, Persistence (computer science), Internal medicine, medicine, Clinical significance, business
Published
2015
Full Text
View/download PDF

30. P0903 : Slow HCV kinetics following sofosbuvir + ribavirin administration in real-life setting of liver transplant recipients with severe recurrent hepatitis C

Author

C. Chialà, R. Canu, Maria Chiara Colombo, Giuseppe Tisone, Francesca Ceccherini-Silberstein, Fausto Zamboni, V.C. Di Maio, Antonio Picciotto, Luciano Milanesi, M. Manuelli, Giorgio Rossi, Ilaria Lenci, A. Di Leo, L. Mameli, M.C. Sorbo, M. Rendina, Daniele Sforza, Roberta Alfieri, Simona Marenco, A. Abedrabbo, Maria Francesca Donato, M.L. Ponti, Martina Milana, R. Ganga, Federica Malinverno, Valeria Cento, C.F. Perno, Marianna Aragri, S. Monico, and Mario Angelico

Subjects
medicine.medical_specialty, Hepatology, Sofosbuvir, business.industry, Ribavirin, Gastroenterology, chemistry.chemical_compound, chemistry, Internal medicine, medicine, In real life, Recurrent hepatitis, business, medicine.drug
Published
2015
Full Text
View/download PDF

31. P0628 : A high genetic heterogeneity in HBsAg can affect immunogenicity in acute hepatitis B infection

Author

Caterina Sagnelli, Romina Salpini, Nicola Coppola, L. Carioti, Mariantonietta Pisaturo, Maria Concetta Bellocchi, C.F. Perno, Claudia Alteri, Marianna Aragri, Mario Starace, Valentina Svicher, Michela Pollicita, A. Battisti, Daniele Armenia, and Evangelista Sagnelli

Subjects
HBsAg, Hepatology, Genetic heterogeneity, business.industry, Immunogenicity, Medicine, Acute hepatitis B, Affect (psychology), business, Virology
Published
2015
Full Text
View/download PDF

32. Does ultra-deep-sequencing in HCV patients treated with boceprevir/telaprevir-based therapy provide an added value in comparison to standard population-sequencing in the detection of resistance?

Author

Giustino Parruti, C.F. Perno, Francesca Ceccherini-Silberstein, Fabio Continenza, M. Puoti, V.C. Di Maio, S. Bruno, Cesare Sarrecchia, Carlo Magni, Daniele Armenia, J. Vecchiet, Mario Angelico, L. Carioti, Giuliano Rizzardini, D. Di Paolo, F. De Luca, Sergio Babudieri, Ilaria Lenci, F. De Leonardis, M. Andreoni, Marianna Aragri, M. Tontodonati, Valeria Micheli, A. De Maria, Antonio Picciotto, Maria Concetta Bellocchi, Maria Stella Mura, Valeria Cento, Ennio Polilli, Lorenzo Nosotti, Simona Francioso, Aldo Bertoli, F.P. Antonucci, and A. Manunta

Subjects
Standard Population, Hepatology, business.industry, Gastroenterology, Ultra deep sequencing, Virology, Telaprevir, chemistry.chemical_compound, chemistry, Boceprevir, Added value, medicine, business, medicine.drug
Published
2014
Full Text
View/download PDF

33. Clinical relevance of next generation sequencing on baseline detection of minority resistance associated variants in HCV-1 patients treated with protease inhibitors

Author

Valeria Micheli, Antonio Picciotto, Aldo Bertoli, Massimo Levrero, C.F. Perno, Ilaria Lenci, Francesca Guerrieri, F.P. Antonucci, Mario Angelico, F. De Leonardis, M. Andreoni, Lorenzo Nosotti, Giustino Parruti, Simona Francioso, Marianna Aragri, M. Santoro, Giuliano Rizzardini, Carlo Magni, F. De Luca, Ludovica Calvo, Valeria Cento, A. Manunta, J. Vecchiet, Francesca Ceccherini-Silberstein, S. Bruno, Daniele Armenia, Maria Concetta Bellocchi, D. Di Paolo, Cesare Sarrecchia, Filomena Morisco, M. Puoti, V.C. Di Maio, Sergio Babudieri, M. Tontodonati, Ennio Polilli, Maria Stella Mura, Simona Marenco, and L. Carioti

Subjects
Protease, Hepatology, business.industry, medicine.medical_treatment, Gastroenterology, Medicine, Clinical significance, business, Bioinformatics, Baseline (configuration management), DNA sequencing
Published
2015
Full Text
View/download PDF

34. A high HBsAg genetic complexity can influence HBV immunogenicity in the setting of acute infection

Author

Claudia Alteri, Mariantonietta Pisaturo, A. Battisti, Marianna Aragri, Evangelista Sagnelli, Valentina Svicher, Maria Concetta Bellocchi, Mario Starace, C.F. Perno, Romina Salpini, Nicola Coppola, L. Carioti, Caterina Sagnelli, Michela Pollicita, Daniele Armenia, Battisti, A, Aragri, M, Coppola, N, Alteri, C, Sagnelli, C, Pisaturo, M, Bellocchi, Mc, Salpini, R, Starace, M, Armenia, D, Carioti, L, Pollicita, M, Sagnelli, E, Perno, Cf, and Svicher, V

Subjects
Genetic complexity, medicine.medical_specialty, HBsAg, Hepatology, business.industry, Family medicine, Immunogenicity, Gastroenterology, Medicine, Acute infection, business, Virology, Mental health
Abstract

A. Battisti 1, M. Aragri1, N. Coppola2, C. Alteri1, C. Sagnelli 3, M. Pisaturo2, M.C. Bellocchi1, R. Salpini1, M. Starace2, D. Armenia1, L. Carioti 1, M. Pollicita1, E. Sagnelli 2, C.F. Perno1, V. Svicher1 1 Department of Experimental Medicine and Surgery, University of Rome “Tor Vergata”, Rome, Italy 2 Department of Mental Health and Public Medicine, Section of Infectious Diseases, Second University of Naples, Naples, Italy 3 Department of Clinical and Experimental Medicine and Surgery, Second University of Naples, Naples, Italy

Published
2015
Full Text
View/download PDF

35. P696 A COMPLEX HBV QUASISPECIES IN RT AND HBsAg CHARACTERIZES PATIENTS WITH ACUTE HEPATITIS B: A REFINED UDPS ANALYSIS

Author

Claudia Alteri, Mario Starace, Marianna Aragri, C.F. Perno, Daniele Armenia, V. Svicher, R. Salpini, Maria Concetta Bellocchi, Caterina Sagnelli, A. Battisti, Evangelista Sagnelli, L. Carioti, Michela Pollicita, Fabio Continenza, Nicola Coppola, Carmine Minichini, and Mariantonietta Pisaturo

Subjects
HBsAg, Hepatology, business.industry, Medicine, Viral quasispecies, Acute hepatitis B, business, Virology
Published
2014
Full Text
View/download PDF

36. Early viral dynamics in HCV-RNA decay and NS3-resistance development predict the risk of failure to first-generation protease inhibitors

Author

Giustino Parruti, Gloria Taliani, Simona Francioso, Ilaria Lenci, F.P. Antonucci, Claudio Maria Mastroianni, Simona Landonio, Laura Ambra Nicolini, Ivana Maida, Valeria Micheli, Antonio Picciotto, D. Di Paolo, Giuliano Rizzardini, Lorenzo Nosotti, F. De Leonardis, Marco Massari, Antonio Gasbarrini, Anna Claudia Pellicelli, Sergio Babudieri, A. Manunta, Jacopo Vecchiet, Francesca Ceccherini-Silberstein, M. Tontodonati, A. De Maria, Ennio Polilli, Maria Stella Mura, Tamara Ursini, Cesare Sarrecchia, Simona Marenco, A. Di Biagio, Marianna Aragri, Massimo Andreoni, Mario Angelico, Valeria Cento, Fosca Niero, Alessandra Mangia, Annalisa Tortora, Alessandro Mancon, M. Siciliano, V.C. Di Maio, Carlo Federico Perno, Carlo Magni, Claudio Viscoli, and Aldo Bertoli

Subjects
NS3, Protease, Hepatology, Resistance development, Viral dynamics, business.industry, medicine.medical_treatment, Gastroenterology, Medicine, business, Virology, First generation
Published
2014
Full Text
View/download PDF

37. Key genetic markers in the full-length HBsAg gene correlate with HBV-driven carcinogenesis by affecting HBsAg secretion and release

Author

Caterina Gori, Pascale Trimoulet, Aldo Bertoli, Valeria Micheli, Valentina Svicher, Carmen Mirabelli, T. Mari, Fosca Niero, Valeria Cento, A. Salso, Gabriele Missale, Carlo Magni, J. Vecchiet, M. Santoro, Francesca Ceccherini-Silberstein, Claudia Alteri, Michela Pollicita, Maria Neumann-Fraune, A. Barlattani, J. Verhejen, Marianna Aragri, Guido Gubertini, C.F. Perno, Giuliano Rizzardini, Massimo Andreoni, Mario Angelico, Caterina Pasquazzi, Romina Salpini, V.C. Di Maio, Cesare Sarrecchia, Hervé Fleury, and N. Iapadre

Subjects
HBsAg, Hepatology, Genetic marker, business.industry, Immunology, Gastroenterology, Medicine, Secretion, business, Carcinogenesis, medicine.disease_cause, Gene, Virology
Published
2014
Full Text
View/download PDF

38. 430 KEY GENETIC SIGNATURES IN THE WHOLE pre-S1/Pre-S2/S GENE CORRELATE WITH HBV-INDUCED CARCINOGENESIS BY AFFECTING HBsAg SECRETION AND RELEASE

Author

Valentina Svicher, Aldo Bertoli, Guido Gubertini, Jacopo Vecchiet, Cesare Sarrecchia, Claudia Alteri, Maria Neumann-Fraune, Jens Verheyen, Massimo Andreoni, Mario Angelico, A. Barlattani, T. Mari, Caterina Pasquazzi, Valeria Cento, Marianna Aragri, Caterina Gori, R. Salpini, Hervé Fleury, N. Iapadre, Pascale Trimoulet, F. Ceccherini-Silberstein, Valeria Micheli, Carmen Mirabelli, C.F. Perno, and V.C. Di Maio

Subjects
HBsAg, Hepatology, Immunology, medicine, Biology, Carcinogenesis, medicine.disease_cause, Gene, Virology
Abstract

430 KEY GENETIC SIGNATURES IN THE WHOLE pre-S1/Pre-S2/S GENE CORRELATE WITH HBV-INDUCED CARCINOGENESIS BY AFFECTING HBsAg SECRETION AND RELEASE V. Svicher, M. Neumann-Fraune, C. Mirabelli, R. Salpini, V. Cento, V.-C. Di Maio, A. Bertoli, C. Alteri, M. Aragri, C. Gori, V. Micheli, G. Gubertini, P. Trimoulet, H. Fleury, J. Vecchiet, N. Iapadre, A. Barlattani, T. Mari, C. Pasquazzi, C. Sarrecchia, F. Ceccherini-Silberstein, M. Andreoni, M. Angelico, J. Verheyen, C.-F. Perno. University of Rome Tor Vergata, Rome, Italy; University of Cologne, Cologne, Germany; National Institute for Infectious Diseases ‘L. Spallanzani’, Rome, “L. Sacco” Hospital, Milan, Italy; Hopital Pellegrin Tripode, Bordeaux, France; “SS Annunziata” Hospital, Chieti, “S Salvatore” Hospital, L’Aquila, “S Giacomo” Hospital, “Regina Margherita” Hospital, “S Andrea” Hospital, Rome, Italy; University of Essen, Essen, Germany E-mail: valentina.svicher@uniroma2.it

Published
2013
Full Text
View/download PDF

39. DECLINE OF PREVALENCE OF RESISTANCE ASSOCIATED SUBSTITUTIONS TO NS3 AND NS5A INHIBITORS AT DAA- FAILURE IN HEPATITIS C VIRUS IN ITALY OVER THE YEARS 2015 TO 2018

Author

Aasld, American Association For The Study Of Liver Diseases, Barbara, Rossetti, Redi, David, Velia Chiara Di Maio, Marianna, Aragri, Stefania, Paolucci, Paglicci, Lorenzo, Chiara, Masetti, Bianca, Bruzzone, Carmine, Minichini, FRANCESCA MONTAGNANI, Valeria, Micheli, Simona, Landonio, Giacomo Zanelli, Elisabetta, Degasperi, Renato, Maserati, Ivana, Maida, Annapaola, Callegaro, Silvia, Barbaliscia, Ada, Bertoli, Claudio, Paternoster, Simona, Marenco, Filomena, Morisco, Vincenza, Calvaruso, Gloria, Taliani, Massimo, Puoti, Giovanni, Cenderello, Adriano De Santis, Miriam, Lichtner, Nicola, Coppola, Roberto, Gulminetti, Valeria, Cento, Maria, Rendina, Elisabetta, Teti, Giustino, Parruti, Tina, Ruggiero, Valeria, Ghisetti, Caterina, Pasquazzi, Laura Ambra Nicolini, Vincenzo, Vullo, Adriano, Pellicelli, Tullio, Prestileo, Raffaele, Cozzolongo, Vincenzo, Sangiovanni, Marco, Biolato, Ilaria, Lenci, Anna, Licata, Antonio, Ciaccio, Valeria Pace Palitti, Alessia, Giorgini, Giuseppe, Cariti, Alessia, Ciancio, Alessio, Aghemo, Vanni, Borghi, Pietro, Andreone, Brunetto, Maurizia R., Teresa, Pollicino, Teresa Antonia Santantonio, Nunzia, Cuomo, Cinzia, Caudai, Sergio, Babudieri, Pietro, Lampertico, Giovanni Battista Gaeta, Giovanni, Raimondo, Massimo, Andreoni, Giuliano, Rizzardini, Mario, Angelico, Carlo Federico Perno, Antonio, Craxì, Maurizio Zazzi, Francesca Ceccherini Silberstein, and and HCV Virology Italian Resistance Network (Vironet C)

Catalog

Books, media, physical & digital resources
See catalog results